KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.
During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.
At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.
KOLs in the retina world reflect on advice they would share with fellows beginning their journey into retina, including the vast opportunities in healthcare and the importance of curiosity and collaboration for revolutionary advancements in retina medicine.
The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.
Prof. Querques broke down perifoveal vascular anomalous complex (PVAC) and telangiectatic capillaries (TelCaps) for congress delegates.
Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies.
During her Ophthalmologica Lecture at the 2025 EURETINA Congress, Prof Cicinelli explained why it's time for a different approach to white spot syndromes.
At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma.
María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works."
Aleksandra Rachitskaya, MD, FASRS, is a member of the Modern Retina editorial advisory board.
The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress.
In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration.
This year's EURETINA meeting boasts a crowd of 10,000 attendees, including delegates, industry leaders, and young retina specialists.
Anat Loewenstein, MD, president of EURETINA, announces the EURETINA Innovation Spotlight (EIS) will return on September 3 this year.
Panelists discuss how they encourage hesitant colleagues to adopt geographic atrophy therapies by emphasizing the importance of staying current with clinical trial data, starting with highly motivated patients who mirror trial populations, and express excitement about the future of precision medicine through biomarker-guided treatment selection, advanced imaging with artificial intelligence integration, late-stage trials targeting vision as primary end points, and innovative approaches like gene therapy and cell therapy that may eventually restore vision.
Panelists discuss how they explain treatment success to patients with geographic atrophy by emphasizing that although the disease will continue to progress, clinical trial data show that the therapy slows the rate of growth by 20% to 30% on average, acknowledging that individual patient responses vary along a bell curve and that preserving retinal tissue is inherently meaningful for visual function even without immediate measurable vision improvements.
Panelists discuss how they manage patients requiring both wet age-related macular degeneration (AMD) and geographic atrophy (GA) treatments by administering injections on separate days rather than on the same day to avoid workflow disruption, address the increased intraocular pressure from the larger 100-µL complement inhibitor dose by allowing patients time to acclimate in the chair with only a small percentage requiring pressure-relieving taps, and acknowledge that although this dual-therapy population represents a minority of their patients undergoing complement modulation, these experienced injection recipients are typically very accepting of additional treatments.
Panelists discuss how they present the modest efficacy of geographic atrophy (GA) therapies to patients by framing treatment as maintenance therapy that slows progression rather than providing improvement, using prior imaging to demonstrate disease advancement, acknowledging the inherent risk of developing wet age-related macular degeneration (AMD) while emphasizing that this preexisting risk is increased with complement inhibitor therapy, and offering hope for more effective future treatments.
Panelists discuss how they approach therapy selection between the 2 FDA-approved geographic atrophy treatments by comparing pegcetacoplan’s potentially greater efficacy signals with avacincaptad pegol’s superior safety profile, with treatment choice often driven by individual patient factors such as motivation level, monocular status, and willingness to accept risk, while emphasizing that starting monthly dosing provides the best fallback position when patients experience treatment fatigue.
Panelists discuss how their management approach for geographic atrophy (GA) has evolved from a “come back in a year” mentality to actively offering treatment discussions within 2 to 3 months, with most patients showing interest in complement inhibitor therapy, particularly those with functional vision remaining who understand the progressive nature of their disease and have vision left to preserve.
Panelists discuss how conversations with patients with geographic atrophy have evolved to emphasize the urgency of early intervention, with clinicians now able to offer hope through available treatments that can slow disease progression, while helping patients understand that their current vision represents the best they will ever have and leveraging family history awareness to motivate treatment consideration.
Panelists discuss how geographic atrophy (GA) presentations show clinical variability across patients while remaining consistently progressive, requiring a combination of imaging modalities including fundus photography, fundus autofluorescence, and OCT for diagnosis and monitoring, with OCT being most practical for routine clinical visits despite fundus autofluorescence serving as the gold standard for clinical trials.
